Neutrophil gelatinase-associated lipocalin increases HLA-G +/FoxP3+ T-regulatory cell population in an in vitro model of PBMC

PLoS ONE

Volumn 9, Issue 2, 2014, Pages

  La Manna, Gaetano ^a   Ghinatti, Giulia ^b   Tazzari, Pier Luigi ^a   Alviano, Francesco ^c   Ricci, Francesca ^a   Capelli, Irene ^a   Cuna, Vania ^a   Todeschini, Paola ^a   Brunocilla, Eugenio ^a   Pagliaro, Pasqualepaolo ^a   Bonsi, Laura ^c   Stefoni, Sergio ^a  

^a UNIVERSITY OF BOLOGNA   (Italy)

^b SECOND UNIVERSITY OF NAPLES   (Italy)

^c UNIVERSITY OF BOLOGNA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ENTEROCHELIN; FICOLL; HLA G ANTIGEN; IRON COMPLEX; NEUTROPHIL GELATINASE ASSOCIATED LIPOCALIN; TRANSCRIPTION FACTOR FOXP3;

ANTIGEN EXPRESSION; ARTICLE; CD4+ CD25+ T LYMPHOCYTE; CD4+ T LYMPHOCYTE; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; FLOW CYTOMETRY; HUMAN; HUMAN CELL; IMMUNOLOGICAL TOLERANCE; IMMUNOMODULATION; IMMUNOPHENOTYPING; IN VITRO STUDY; LYMPHOCYTE SUBPOPULATION; NORMAL HUMAN; PERIPHERAL BLOOD MONONUCLEAR CELL; REGULATORY T LYMPHOCYTE;

ACUTE-PHASE PROTEINS; CD4-POSITIVE T-LYMPHOCYTES; ENTEROBACTIN; FORKHEAD TRANSCRIPTION FACTORS; HLA-G ANTIGENS; HUMANS; IMMUNOPHENOTYPING; LEUKOCYTES, MONONUCLEAR; LIPOCALINS; LYMPHOCYTE ACTIVATION; PROTO-ONCOGENE PROTEINS; T-LYMPHOCYTE SUBSETS; T-LYMPHOCYTES, REGULATORY;

EID: 84897909178     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0089497     Document Type: Article

References (49)

1. Chakraborty S, Kaur S, Guha S, Batra SK (2012) The multifaceted roles of neutrophil gelatinase associated lipocalin (NGAL) in inflammation and cancer. Biochim Biophys Acta 1826(1):129-169.
2. Goetz DH, Holmes MA, Borregaard N, Bluhm ME, Raymond KN, et al (2002) The neutrophil lipocalin NGAL is a bacteriostatic agent that interferes with siderophore-mediated iron acquisition. Mol Cell 10(5):1033-1043. (Pubitemid 36001971)
3. Flo TH, Smith KD, Sato S, Rodriguez DJ, Holmes MA, et al (2004) Lipocalin 2 mediates an innate immune response to bacterial infection by sequestrating iron. Nature 432(7019):917-921. (Pubitemid 40037155)
4. Roudkenar MH, Halabian R, Bahmani P, Roushandeh AM, Kuwahara Y, et al (2011) Neutrophil gelatinase-associated lipocalin: a new antioxidant that exerts its cytoprotective effect independent on Heme Oxygenase-1. Free Radic Res 45(7):810-819.
5. Haase M, Bellomo R, Devarajan P, Schlattmann P, Haase-Fielitz A (2009) NGAL Meta-analysis Investigator Group. Accuracy of neutrophil gelatinase-associated lipocalin (NGAL) in diagnosis and prognosis in acute kidney injury: a systematic review and meta-analysis. Am J Kidney Dis 54(6):1012-1024.
6. An S, Zang X, Yuan W, Zhuge Y, Yu Q (2013) Neutrophil Gelatinase-Associated Lipocalin (NGAL) May Play a Protective Role Against Rats Ischemia/Reperfusion Renal Injury via Inhibiting Tubular Epithelial Cell Apoptosis. Ren Fail 35(1):143-1497.
7. Entin-Meer M, Ben-Shoshan J, Maysel-Auslender S, Levy R, Goryainov P, et al (2012) Accelerated renal fibrosis in cardiorenal syndrome is associated with longterm increase in urine neutrophil gelatinase-associated lipocalin levels. Am J Nephrol 36(2):190-200.
8. Ronco C, Cruz D, Noland BW (2012) Neutrophil gelatinase-associated lipocalin curve and neutrophil gelatinase-associated lipocalin extended-range assay: a new biomarker approach in the early diagnosis of acute kidney injury and cardiorenal syndrome. Semin Nephrol 32(1):121-128.
9. Villalva C, Sorel N, Bonnet ML, Guilhot J, Mayeur-Rousse C, et al (2008) Neutrophil gelatinase-associated lipocalin expression in chronic myeloid leukemia. Leuk Lymphoma May 49(5):984-988.
10. Alonci A, Allegra A, Russo S, Penna G, Bellomo G, et al (2012) Imatinib mesylate therapy induces reduction in neutrophil gelatinase-associated lipocalin serum levels and increase in leptin concentrations in chronic myeloid leukemia patients in molecular remission. Acta Haematol 127(1):1-6.
11. Zhang PX, Zhang FR, Xie JJ, Tao LH, Lü Z, et al (2012) Expression of NGAL and NGALR in human embryonic, fetal and normal adult tissues. Mol Med Report 6(4):716-722.
12. Costa D, Biticchi R, Negrini S, Tasso R, Cancedda R, et al (2010) Lipocalin-2 controls the expression of SDF-1 and the number of responsive cells in bone. Cytokine 51(1):47-52.
13. Heyne N, Kemmner S, Schneider C, Nadalin S, Königsrainer A, et al. (2012) Urinary Neutrophil Gelatinase-Associated Lipocalin Accurately Detects Acute Allograft Rejection Among Other Causes of Acute Kidney Injury in Renal Allograft Recipients. Transplantation. 93(12):1252-1257.
14. Bu DX, Hemdahl AL, Gabrielsen A Fuxe J, Zhu C, et al (2006) Induction of neutrophil gelatinase-associated lipocalin in vascular injury via activation of nuclear factor-kappaB. Am J Pathol 169(6): 2245-2253. (Pubitemid 351181982)
15. Matsuo S, Yamazaki S, Takeshige K Muta T (2007) Crucial roles of binding sites for NFkappaB and C/EBPs in IkappaB-zeta-mediated transcriptional activation. Biochem J 405(3): 605-615. (Pubitemid 47172059)
16. Parikh CR, Jani A, Mishra J, Ma Q, Kelly C, et al (2006) Urine NGAL and IL-18 are predictive biomarkers for delayed graft function following kidney transplantation. Am J Transplant 6(7): 1639-1645. (Pubitemid 43945804)
17. Mishra J, Ma Q, Prada A, Mitsnefes M, Zahedi K, et al (2003) Identification of neutrophil gelatinase-associated lipocalin as a novel early urinary biomarker for ischemic renal injury. J Am Soc Nephrol 14(10):2534-2543. (Pubitemid 37169339)
18. Mishra J, Mori K, Ma Q, Kelly C, Barasch J, et al (2004) Neutrophil gelatinase-associated lipocalin: a novel early urinary biomarker for cisplatin nephrotoxicity. Am J Nephrol 24(3):307-315. (Pubitemid 39070114)
19. Devarajan P (2006) Update on mechanisms of ischemic acute kidney injury. J Am Soc Nephrol 17(6):1503-1520.
20. Johnson AC, Becker K, Zager RA (2010) Parenteral iron formulations differentially affect MCP-1, HO-1, and NGAL gene expression and renal responses to injury. Am J Physiol Renal Physiol 299(2):F426-435.
21. Byrne SL, Krishnamurthy D, Wessling-Resnick M (2013) Pharmacology of Iron Transport. Annu Rev Pharmacol Toxicol 53:17-36.
22. Schmidt-Ott KM, Mori K, Li JY, Kalandadze A, Cohen DJ, et al (2007) Dual action of neutrophil gelatinase-associated lipocalin. J Am Soc Nephrol 18(2): 407-413. (Pubitemid 46193306)
23. Mori K, Lee HT, Rapoport D, Drexler IR, Foster K, et al (2005) Endocytic delivery of lipocalin-siderophore-iron complex rescues the kidney from ischemia-reperfusion injury. J Clin Invest 115(3): 610-621. (Pubitemid 40322235)
24. Devarajan P, Mishra J, Supavekin S, Patterson LT, Potter S (2003) Gene expression in early ischemic renal injury: clues towards pathogenesis, biomarker discovery, and novel therapeutics. Mol Genet Metab 80(4):365-376. (Pubitemid 37491197)
25. Bonventre JV (2003) Dedifferentiation and proliferation of surviving epithelial cells in acute renal failure. J Am Soc Nephrol 14 Suppl 1:S55-61.
26. Hammerman MR (2000) Recapitulation of phylogeny by ontogeny in nephrology. Kidney Int 57(2):742-755.
27. Yang J, Goetz D, Li JY, Wang W, Mori K, et al (2002) An iron delivery pathway mediated by a lipocalin. Mol Cell 10(5):1045-1056. (Pubitemid 35453824)
28. Akagi R, Takahashi T, Sassa S (2005) Cytoprotective effects of heme oxygenase in acute renal failure. Contrib Nephrol 148:70-85. (Pubitemid 43264923)
29. Mao S, Jiang T, Shang G, Wu Z, Zhang N (2011) Increased expression of neutrophil gelatinase-associated lipocalin receptor by interleukin-1 b in human mesangial cells via MAPK/ERK activation. Int J Mol Med 27(4): 555-560.
30. Bennett CL,Christie J, Ramsdell F, Brunkow ME,Ferguson PJ, et al (2001) The immune dysregulation, polyendocrinopathy, enteropathy, X- linked syndrome (IPEX) is caused by mutations of FOXP3. Nat.Genet 27:20-21. (Pubitemid 32044513)
31. Costantino CM, Baecher-Allan CM, Hafler DA (2008) Human regulatory T cells and autoimmunity. Eur J Immunol 38:921-924.
32. LeMaoult J, Krawice-Radanne I, Dausset J, Carosella ED (2004) HLA-G1-expressing antigen presenting cells induce immunosuppressive CD4- T cells. Proc Natl Acad Sci U S A 101:7064-7069. (Pubitemid 38596443)
33. LeMaoult J, Caumartin J, Daouya M, Favier B, Le Rond S, et al (2007) Immune regulation by pretenders: cell-to-cell transfers of HLA-G make effector T cells act as regulatory cells. Blood 109:2040-2048. (Pubitemid 46348204)
34. Le Rond S, Azéma C, Krawice-Radanne I, Durrbach A, Guettier C, et al (2006) Evidence to support the role of HLA-G5 in allograft acceptance through induction of immunosuppressive/regulatory T cells. J Immunol 176:3266-3276.
35. Naji A, Le Rond S, Durrbach A, Krawice-Radanne I, Creput C, et al (2007) CD3+CD4low and CD3+CD8low are induced by HLA-G: novel human peripheral blood suppressor T-cell subsets involved in transplant acceptance. Blood 110:3936-3948. (Pubitemid 350248449)
36. Ohta A, Kini R, Ohta A, Subramanian M, Madasu M, et al (2012) The development and immunosuppressive functions of CD4(+) CD25(+) FoxP3(+) regulatory T cells are under influence of the adenosine-A2A adenosine receptor pathway. Front Immunol 3:190.
37. Li L, Huang L, Ye H, Song SP, Bajwa A, et al (2012) Dendritic cells tolerized with adenosine A2AR agonist attenuate acute kidney injury. J Clin Invest 122(11): 3931-3942.
38. Adiyanti SS, Loho T (2012) Acute Kidney Injury (AKI) Biomarker. Acta Med Indones44(3):246-255.
39. Xu S, Venge P (2000) Lipocalins as biochemical markers of disease. Biochim Biophys Acta 1482(1-2): 298-307.
40. Cowland JB, Sørensen OE, Sehested M, Borregaard N (2003) Neutrophil gelatinase-associated lipocalin is up-regulated in human epithelial cells by IL-1 beta, but not by TNF-alpha. J Immunol Dec 15;171(12):6630-6639.
41. Hemdahl AL, Gabrielsen A, Zhu C, Eriksson P, Hedin U, et al (2006) Expression of neutrophil gelatinase-associated lipocalin in atherosclerosis and myocardial infarction. Arterioscler Thromb Vasc Biol 26(1):136-142. (Pubitemid 43732240)
42. Carosella ED, Favier B, Rouas-Freiss N, Moreau P, Lemaoult J (2008) Beyond the increasing complexity of the immunomodulatory HLA-G molecule. Blood 111(10): 4862-4870.
43. Christiansen OB (2013) Reproductive immunology. Mol Immunol 55(1):8-15.
44. Evstatiev R, Gasche C (2012) Iron sensing and signalling. Gut 61(6):933-952.
45. Venken K, Hellings N, Thewissen M, Somers V, Hensen K, et al (2008) Compromised CD4+ CD25(high) regulatory T-cell function in patients with relapsing-remitting multiple sclerosis is correlated with a reduced frequency of FOXP3-positive cells and reduced FOXP3 expression at the single-cell level. Immunology 123(1):79-89. (Pubitemid 350255996)
46. Dejaco C, Duftner C, Grubeck-Loebenstein B, Schirmer M, et al (2006) Imbalance of regulatory T cells in human autoimmune diseases. Immunology Mar 117(3):289-300.
47. D'Arena G, Rossi G, Vannata B, Deaglio S, Mansueto G, et al (2012) Regulatory T-Cells in Chronic Lymphocytic Leukemia and Autoimmune Diseases. Mediterr J Hematol Infect Dis 4(1):e2012053.
48. Dummer CD, Carpio VN, Gonçalves LF, Manfro RC, Veronese FV, et al (2012) FOXP3+ regulatory T cells: from suppression of rejection to induction of renal allograft tolerance. Transpl Immunol 26(1):1-10.
49. Issa F, Wood KJ (2012) Translating tolerogenic therapies to the clinic - where do we stand? Front Immunol 3:254.